Arbutus biopharma corporation ABUS.US AI Analysis
BetaUS StockHealthcare
(No presentation for ABUS)
ABUS Value Score
3
24
15
Average Growth
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
ABUS Value Strategy Backtest
The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.
Entry
Exit
The Backtest Result of ABUS from 2007-07-26 till Now
- -10.89%
- Cumulative Return
- -0.64%
- Annual Return
- 58.38%
- Volatility
- -0.01
- Sharpe Ratio
Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from July, 2007 to June, 2025. (Total Trades: 5)
| ABUS | Sector | US Overall Market | |
|---|---|---|---|
| Wining Rate | 60% | 47% | 55% |
| Avg Return | 7.6% | 46.4% | 58.3% |
| Avg Profit | 34.3% | 145.8% | 131.3% |
| Avg Loss | -32.5% | -40.5% | -31% |
| Avg Risk-Reward Ratio | 105.7% | 360% | 423.5% |